Aura Biosciences (NASDAQ:AURA – Get Free Report) announced its earnings results on Monday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.08, FiscalAI reports.
Aura Biosciences Trading Down 2.5%
Shares of NASDAQ:AURA traded down $0.19 during mid-day trading on Wednesday, reaching $7.46. The company had a trading volume of 157,310 shares, compared to its average volume of 571,287. The firm has a market cap of $773.68 million, a price-to-earnings ratio of -4.56 and a beta of 0.41. The company’s 50-day moving average price is $6.55 and its 200-day moving average price is $6.74. Aura Biosciences has a one year low of $4.73 and a one year high of $9.53.
More Aura Biosciences News
Investors following AURA have been watching these news items:
- Positive Sentiment: Aura shares climbed 12.7% after the company reported a quarterly loss of $0.29 per share, narrower than analysts’ expected loss of $0.37. The earnings beat is the clearest reported catalyst for the stock’s recent strength. Article: Aura Biosciences shares climb on better-than-expected earnings
- Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, including improving its FY2027 forecast from a $1.63 loss to a $1.23 loss and its FY2029 estimate from a $0.31 loss to $0.01 in earnings. The firm maintained a Buy rating and an $18 price target, supporting a more optimistic long-term outlook. Aura Biosciences analyst coverage
- Neutral Sentiment: A report listed short interest at zero shares and a 0.0-day short-interest ratio, but also described short interest as having increased. The conflicting wording makes this data difficult to interpret. Aura Biosciences short-interest information
Analyst Upgrades and Downgrades
AURA has been the topic of several analyst reports. Citigroup restated a “market outperform” rating on shares of Aura Biosciences in a report on Tuesday. HC Wainwright decreased their price objective on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen lowered shares of Aura Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, October 12th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aura Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.
View Our Latest Analysis on AURA
Aura Biosciences Company Profile
Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.
Read More
- Five stocks we like better than Aura Biosciences
- IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
- On Holding’s Sell-Off Overlooks a Key Part of Its Earnings Story
- Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand
- Alphabet Escalates AI Chip Rivalry With NVIDIA
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
